UK-based Porton Biopharma has begun the construction of a new pharmaceutical development facility, which will provide state-of–the–art facilities for its teams of scientists. The 530 square meter building has been designed to reflect modern best practice in laboratory design and will replace older facilities. The new facility will feature a fermentation suite with a range of bench-scale reactors and a down-stream processing suite for activities such as filtration and chromatography, all supported by preparation areas and a plant room.

The company said in addition to improving processes and yields for its own products, the facilities are to be used for developmental contract work for customers who wish to translate their research into clinical outcomes.

“My team are really looking forward to the completion of this new state-of-the-art facility later in the year and all the new equipment that they will be available to help deliver increased benefits for our customers and their future patients,” said Trevor Marks, director of development, Porton BioPharma.